Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has announced that President Dr. Jean Pierre Wery has moved into the role of chief executive officer.

In addition to Dr. Wery's recent nomination as CEO, Dr. Alex Wu, co-founder of CrownBio takes the role of president and chief strategy officer, while Eva Ho has been appointed chief financial officer.

"In 2016 CrownBio has experienced unprecedented growth with increasing demand for our Immuno-Oncology and Cardiovascular and Metabolic Disease services and models," said Wery. "As newly appointed CEO my objective is to foster the development of new products, cutting-edge technologies, and services for oncology and metabolic disease, while contemplating a possible expansion into new therapeutic areas."

To further demonstrate CrownBio's commitment to support its global growth, the Board of Directors has chosen Ms. Ho for the role of CFO. Ho brings years of experience in financial planning and analysis, having led the financial operations of well renowned global companies. Ho will take on Bing Zhu's previous role, who has now been appointed chief operating officer.

The consolidation of CrownBio's leadership team demonstrates the company's dedication to provide an experienced management team to drive forward the advancement of drug discovery worldwide.